Amgen Inc, updating the first trial of its bispecific antibody for multiple myeloma, said on Monday seven out of 10 patients given the second-highest dose of AMG420 responded to the drug, including four with no detectable cancer.
Amgen antibody shows promise in myeloma trial, gets FDA fast track
![Amgen antibody shows promise in myeloma trial, gets FDA fast track]()
Reviewed by jenisht
on
December 04, 2018
Rating:
No comments: